Suggested remit: To appraise the clinical and cost effectiveness of zanidatamab within its marketing authorisation for treating HER2-positive advanced biliary tract cancer after 1 or more systemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results